Home/Pipeline/STAR-0310

STAR-0310

Atopic Dermatitis

Phase 1Investigational (Non-Core)

Key Facts

Indication

Atopic Dermatitis

Phase

Phase 1

Status

Investigational (Non-Core)

Company

BioCryst Pharmaceuticals

About BioCryst Pharmaceuticals

Founded in 1986, BioCryst Pharmaceuticals is a global, commercial-stage biotech company headquartered in Durham, North Carolina, focused on discovering and developing novel treatments for rare diseases. Its core expertise lies in structure-guided drug design, which it uses to create highly selective oral and injectable therapies. The company has successfully commercialized ORLADEYO for HAE and is advancing a pipeline of investigational candidates, including navenibart for HAE and BCX17725 for Netherton syndrome, while also marketing RAPIVAB for influenza.

View full company profile

Therapeutic Areas

Rare Diseases Hereditary Angioedema Complement-Mediated Diseases Dermatology Infectious Diseases

Other Atopic Dermatitis Drugs

Drug	Company	Phase	Status
Lebrikizumab	Eli Lilly	Phase 3	Active
Dupixent	Sanofi	Commercial	Marketed
ASP2408	Astellas Pharma	Phase 2	Active
KW-6356	Kyowa Kirin	Phase 2	Active
KHK4083	Kyowa Kirin	Phase 2	Active
Opzelura (ruxolitinib cream)	Ono Pharmaceutical	Approved	Commercial
ONO-7913	Ono Pharmaceutical	Phase 2	Active
KT-474	Kymera Therapeutics	Phase 2	Active
GRC 27864	Glenmark Pharmaceuticals	Phase 2	Active
ARQ-234	Arcutis Biotherapeutics	Preclinical/Phase 1	Investigational
Rezpegaldesleukin	Nektar Therapeutics	Phase 2b	Active, not recruiting
ZL-1503	Zai Lab	Phase (Early Clinical)	Progressing into clinic